Acute Myeloid Leukemia (AML) Clinical Trials

15 studies are recruiting for acute myeloid leukemia (aml) in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

   The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate [Ca-EDTA] and dimercaptosuccinic acid [DMSA]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy al…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06811233 on ClinicalTrials.gov

2. Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

   Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Banner MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   115 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT07007312 on ClinicalTrials.gov

3. Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

   This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UMPC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Sawa Ito, MD

   See if you can join NCT07565220 on ClinicalTrials.gov

4. TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

   The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the mode…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT07302776 on ClinicalTrials.gov

5. Niclosamide in Pediatric Patients With Relapsed and Refractory AML

   Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

   Stage

   Phase 1

   Ages

   2 to 25

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT05188170 on ClinicalTrials.gov

6. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

   The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

   Stage

   Phase 1

   Ages

   12 to 80

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05092451 on ClinicalTrials.gov

7. CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

   This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone…

   Stage

   Phase 1

   Ages

   0 to 29

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Stephan Grupp MD PhD

   See if you can join NCT07464951 on ClinicalTrials.gov

8. Caris Chromoseq Data Collection

   The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Caris Life Sciences, Phoenix, Arizona

   Run by

   Caris Science, Inc.

   See if you can join NCT07680868 on ClinicalTrials.gov

9. A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

   The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also look for the highest dose of the combination o…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05756777 on ClinicalTrials.gov

10. Ivosidenib as Post-HSCT Maintenance for AML

    This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Emory University Hospital, Atlanta, Georgia

    Locations

    6 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06707493 on ClinicalTrials.gov

11. A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

    The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received standard chemotherapy and are planning to have an allogeneic hematopoieti…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06773208 on ClinicalTrials.gov

12. A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

    This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Stanford, California

    Locations

    7 in total

    Run by

    Solu Therapeutics, Inc

    See if you can join NCT06950034 on ClinicalTrials.gov

13. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06398457 on ClinicalTrials.gov

14. APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

    A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    7 in total

    Run by

    Aptevo Therapeutics

    See if you can join NCT06634394 on ClinicalTrials.gov

15. Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

    The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR], Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with partial hematologic recovery [CRh], th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCLA Medical Center, Los Angeles, California

    Locations

    9 in total

    Run by

    Bio-Path Holdings, Inc.

    See if you can join NCT02781883 on ClinicalTrials.gov